{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:19:23Z","timestamp":1792815563773,"version":"4.5.0"},"reference-count":119,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Neurol"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The rates of opioid use and opioid related deaths are escalating in the United States. Despite this, evidence-based treatments for Opioid Use Disorder are underutilized. There are three medications FDA approved for treatment of Opioid Use Disorder: Methadone, Buprenorphine, and Naltrexone. This article reviews the history, criteria, and mechanisms associated with Opioid Use Disorder. Pertinent pharmacology considerations, treatment strategies, efficacy, safety, and challenges of Methadone, Buprenorphine, and Naltrexone are outlined. Lastly, a practical decision making algorithm is discussed to address pertinent psychiatric and medical comorbidities when prescribing pharmacology for Opioid Use Disorder.<\/jats:p>","DOI":"10.1055\/s-0044-1787571","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T22:59:40Z","timestamp":1717801180000},"page":"441-451","source":"Crossref","is-referenced-by-count":16,"title":["Opioid Maintenance Therapy: A Review of Methadone, Buprenorphine, and Naltrexone Treatments for Opioid Use Disorder"],"prefix":"10.1055","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5758-704X","authenticated-orcid":false,"given":"David C.","family":"Fipps","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler S.","family":"Oesterle","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhanu P.","family":"Kolla","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"116728","DOI":"10.1016\/j.jns.2020.116728","article-title":"Medication-assisted therapies for opioid use disorders in patients with chronic pain","volume":"411","author":"T S Oesterle","year":"2020","journal-title":"J Neurol Sci"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.janh.2017.02.001","article-title":"The chemical history of morphine: an 8000-year journey, from resin to de-novo synthesis","volume":"3","author":"K Brook","year":"2017","journal-title":"J Anesth Hist"},{"issue":"12","key":"ref3","doi-asserted-by":"crossref","first-page":"5391","DOI":"10.1073\/pnas.90.12.5391","article-title":"A brief history of opiates, opioid peptides, and opioid receptors","volume":"90","author":"M J Brownstein","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"07","key":"ref4","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2174\/1381612043452974","article-title":"Pain treatment: a historical overview","volume":"10","author":"R Sabatowski","year":"2004","journal-title":"Curr Pharm Des"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1146\/annurev-publhealth-031914-122957","article-title":"The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction","volume":"36","author":"A Kolodny","year":"2015","journal-title":"Annu Rev Public Health"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1524-9042(03)00033-X","article-title":"Accuracy of emergency nurses in assessment of patients' pain","volume":"4","author":"K Puntillo","year":"2003","journal-title":"Pain Manag Nurs"},{"issue":"11","key":"ref7","doi-asserted-by":"crossref","first-page":"885","DOI":"10.7326\/0003-4819-113-11-885","article-title":"Improving outcomes of analgesic treatment: is education enough?","volume":"113","author":"M B Max","year":"1990","journal-title":"Ann Intern Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.15585\/mmwr.mm675152e1","article-title":"Drug and opioid-involved overdose deaths - United States, 2013-2017","volume":"67","author":"L Scholl","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425787","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR)","author":"American Psychiatric Association","year":"2022"},{"issue":"39","key":"ref11","doi-asserted-by":"crossref","first-page":"16446","DOI":"10.1073\/pnas.1105418108","article-title":"Neuronal circuits underlying acute morphine action on dopamine neurons","volume":"108","author":"M Jalabert","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref12","volume-title":"Neurobiology of opioids","author":"J D Jones","year":"2021","edition":"6th ed."},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1176\/appi.ajp.20220699","article-title":"Opioid use disorder: pernicious and persistent","volume":"179","author":"C L Bergeria","year":"2022","journal-title":"Am J Psychiatry"},{"issue":"06","key":"ref14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2217\/pmt-2017-0028","article-title":"Therapies and mechanisms of opioid withdrawal","volume":"7","author":"N E Burma","year":"2017","journal-title":"Pain Manag (Lond)"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/bjp.2008.51","article-title":"The neurocircuitry of addiction: an overview","volume":"154","author":"M W Feltenstein","year":"2008","journal-title":"Br J Pharmacol"},{"issue":"12","key":"ref16","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.molmed.2006.10.005","article-title":"Drug addiction: the neurobiology of disrupted self-control","volume":"12","author":"R D Baler","year":"2006","journal-title":"Trends Mol Med"},{"issue":"08","key":"ref17","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1176\/appi.ajp.162.8.1403","article-title":"The neural basis of addiction: a pathology of motivation and choice","volume":"162","author":"P W Kalivas","year":"2005","journal-title":"Am J Psychiatry"},{"issue":"41","key":"ref18","doi-asserted-by":"crossref","first-page":"13879","DOI":"10.1523\/JNEUROSCI.2711-15.2015","article-title":"Pain and poppies: the good, the bad, and the ugly of opioid analgesics","volume":"35","author":"T Trang","year":"2015","journal-title":"J Neurosci"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev-neuro-080317-061522","article-title":"Endogenous and exogenous opioids in pain","volume":"41","author":"G Corder","year":"2018","journal-title":"Annu Rev Neurosci"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.tins.2011.11.005","article-title":"The neurobiology of anhedonia and other reward-related deficits","volume":"35","author":"A Der-Avakian","year":"2012","journal-title":"Trends Neurosci"},{"issue":"07","key":"ref21","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.biopsych.2010.10.021","article-title":"Deletion of the \u03b4 opioid receptor gene impairs place conditioning but preserves morphine reinforcement","volume":"69","author":"J Le Merrer","year":"2011","journal-title":"Biol Psychiatry"},{"issue":"13","key":"ref22","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1038\/s41386-018-0225-3","article-title":"Untangling the complexity of opioid receptor function","volume":"43","author":"R J Valentino","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pharmthera.2017.10.021","article-title":"Analysis of natural product regulation of opioid receptors in the treatment of human disease","volume":"184","author":"S Badal","year":"2018","journal-title":"Pharmacol Ther"},{"issue":"06","key":"ref24","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/ALN.0b013e318238bba6","article-title":"Molecular mechanisms of opioid receptor-dependent signaling and behavior","volume":"115","author":"R Al-Hasani","year":"2011","journal-title":"Anesthesiology"},{"issue":"02","key":"ref25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1177\/204946370800100202","article-title":"Basic opioid pharmacology","volume":"1","author":"J Williams","year":"2008","journal-title":"Rev Pain"},{"issue":"05","key":"ref26","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.cell.2017.10.035","article-title":"Bias factor and therapeutic window correlate to predict safer opioid analgesics","volume":"171","author":"C L Schmid","year":"2017","journal-title":"Cell"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/978-3-642-41199-1_22","article-title":"\u03b2-arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia","volume":"219","author":"K M Raehal","year":"2014","journal-title":"Handb Exp Pharmacol"},{"issue":"04","key":"ref28","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/pm\/pny307","article-title":"Challenges with implementing the Centers for Disease Control and Prevention opioid guideline: a consensus panel report","volume":"20","author":"K Kroenke","year":"2019","journal-title":"Pain Med"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/ADM.0000000000000359","article-title":"A case of opioid overdose and subsequent death after medically supervised withdrawal: the problematic role of rapid tapers for opioid use disorder","volume":"12","author":"D C Chang","year":"2018","journal-title":"J Addict Med"},{"issue":"22","key":"ref30","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMp1402780","article-title":"Medication-assisted therapies\u2013tackling the opioid-overdose epidemic","volume":"370","author":"N D Volkow","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"ref31","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.mayocp.2019.03.029","article-title":"Medication-assisted treatment for opioid-use disorder","volume":"94","author":"T S Oesterle","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"ref32","volume-title":"Methadone and buprenorphine maintenance treatment of opioid-related disorders","author":"E C Strain","year":"2021","edition":"6th ed."},{"issue":"14","key":"ref33","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","article-title":"Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence","volume":"41","author":"C B Eap","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"ref34","volume-title":"Pharmacology of Methadone in the Treatment of Opioid Dependence","author":"S L Walsh","year":"2005"},{"issue":"02","key":"ref35","doi-asserted-by":"crossref","first-page":"PL45","DOI":"10.1016\/0024-3205(94)00937-6","article-title":"The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine","volume":"56","author":"K Kristensen","year":"1995","journal-title":"Life Sci"},{"issue":"11","key":"ref36","first-page":"CD008025","article-title":"Methadone for chronic non-cancer pain in adults","volume":"11","author":"S Haroutiunian","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"04","key":"ref37","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/archinte.1966.00290160004002","article-title":"Narcotic blockade","volume":"118","author":"V P Dole","year":"1966","journal-title":"Arch Intern Med"},{"key":"ref38","first-page":"347","article-title":"Methadone maintenance treatment (MMT): a review of historical and clinical issues","volume":"67","author":"H Joseph","year":"2000","journal-title":"Mt Sinai J Med"},{"key":"ref39","volume-title":"The Effectiveness of Methadone Maintenance Treatment","author":"J Ball","year":"2012"},{"issue":"04","key":"ref40","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jpain.2014.01.494","article-title":"Methadone safety: a clinical practice guideline from the American Pain Society and College on problems of drug dependence, in collaboration with the Heart Rhythm Society","volume":"15","author":"R Chou","year":"2014","journal-title":"J Pain"},{"issue":"02","key":"ref41","doi-asserted-by":"crossref","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"S E Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/bmj.309.6960.997","article-title":"Methadone maintenance treatment in opiate dependence: a review","volume":"309","author":"M Farrell","year":"1994","journal-title":"BMJ"},{"issue":"03","key":"ref43","first-page":"CD002209","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","volume":"2009","author":"R P Mattick","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"03","key":"ref44","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study","volume":"169","author":"M R Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"issue":"10","key":"ref45","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1176\/appi.ajp.2018.17101112","article-title":"Medications for alcohol and opioid use disorders and risk of suicidal behavior, accidental overdoses, and crime","volume":"175","author":"Y Molero","year":"2018","journal-title":"Am J Psychiatry"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.2147\/IJGM.S295461","article-title":"Therapeutic approaches to opioid use disorder: what is the current standard of care?","volume":"14","author":"J A Carley","year":"2021","journal-title":"Int J Gen Med"},{"issue":"04","key":"ref47","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jpain.2014.01.495","article-title":"Methadone overdose and cardiac arrhythmia potential: findings from a review of the evidence for an American Pain Society and College on problems of drug dependence clinical practice guideline","volume":"15","author":"R Chou","year":"2014","journal-title":"J Pain"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.drugalcdep.2012.09.016","article-title":"Corrected QT interval during treatment with methadone and buprenorphine\u2013relation to doses and serum concentrations","volume":"129","author":"M Stallvik","year":"2013","journal-title":"Drug Alcohol Depend"},{"issue":"02","key":"ref49","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1097\/AOG.0000000000002235","article-title":"Committee opinion no. 711: opioid use and opioid use disorder in pregnancy","volume":"130","author":"Committee Opinion No","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"05","key":"ref50","first-page":"854","article-title":"Opioid detoxification in pregnancy","volume":"92","author":"J S Dashe","year":"1998","journal-title":"Obstet Gynecol"},{"issue":"03","key":"ref51","doi-asserted-by":"crossref","first-page":"267.e1","DOI":"10.1016\/j.ajog.2013.05.026","article-title":"The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy","volume":"209","author":"R D Stewart","year":"2013","journal-title":"Am J Obstet Gynecol"},{"issue":"07","key":"ref52","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/phar.1958","article-title":"Methadone, buprenorphine, and naltrexone for the treatment of opioid use disorder in pregnant women","volume":"37","author":"T H Tran","year":"2017","journal-title":"Pharmacotherapy"},{"key":"ref53","volume-title":"Highlights of prescribing information: dolophine (methadone hydrochloride)","author":"U.S. Food and Drug Administration","year":"2014"},{"issue":"03","key":"ref54","doi-asserted-by":"crossref","first-page":"e796","DOI":"10.1542\/peds.2013-1985","article-title":"The transfer of drugs and therapeutics into human breast milk: an update on selected topics","volume":"132","author":"H C Sachs","year":"2013","journal-title":"Pediatrics"},{"key":"ref55","volume-title":"Opioid antagonist treatment of opioid-related disorders","author":"M Capata","year":"2021","edition":"6th ed."},{"issue":"01","key":"ref56","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamainternmed.2017.6015","article-title":"Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis","volume":"178","author":"M Brunstr\u00f6m","year":"2018","journal-title":"JAMA Intern Med"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.forsciint.2015.09.021","article-title":"Methadone related deaths compared to all prescription related deaths","volume":"257","author":"R Lev","year":"2015","journal-title":"Forensic Sci Int"},{"issue":"08","key":"ref58","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.2196\/jmir.2810","article-title":"Crowdsourcing black market prices for prescription opioids","volume":"15","author":"N Dasgupta","year":"2013","journal-title":"J Med Internet Res"},{"issue":"02","key":"ref59","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/PAF.0b013e3181e8af3d","article-title":"The methadone epidemic: methadone-related deaths on the rise in Vermont","volume":"32","author":"M E Madden","year":"2011","journal-title":"Am J Forensic Med Pathol"},{"issue":"01","key":"ref60","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40122-019-00143-6","article-title":"A narrative pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain","volume":"9","author":"J Gudin","year":"2020","journal-title":"Pain Ther"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.drugalcdep.2018.05.010","article-title":"Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program","volume":"189","author":"Z M Weinstein","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0376-8716(03)00060-7","article-title":"Buprenorphine: how to use it right","volume":"70","author":"R E Johnson","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0376-8716(03)00056-5","article-title":"The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic","volume":"70","author":"S L Walsh","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"01","key":"ref64","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0376-8716(90)90136-3","article-title":"Effects of sublingually given naloxone in opioid-dependent human volunteers","volume":"25","author":"K L Preston","year":"1990","journal-title":"Drug Alcohol Depend"},{"issue":"25","key":"ref65","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/adaw.33116","article-title":"Brixadi, Sublocade competitor, resubmits application to FDA","volume":"33","year":"2021","journal-title":"Alcohol Drug Abuse Wkly"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0376-8716(85)90067-5","article-title":"Buprenorphine","volume":"14","author":"J W Lewis","year":"1985","journal-title":"Drug Alcohol Depend"},{"issue":"04","key":"ref67","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archpsyc.1978.01770280111012","article-title":"Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction","volume":"35","author":"D R Jasinski","year":"1978","journal-title":"Arch Gen Psychiatry"},{"key":"ref70","volume-title":"Removal of DATA Waiver (X-Waiver) Requirement","author":"U.S. Department of Health & Human Services","year":"2023"},{"issue":"12","key":"ref71","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/j.mayocp.2020.10.011","article-title":"Substance use disorders and telehealth in the COVID-19 pandemic era: a new outlook","volume":"95","author":"T S Oesterle","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"01","key":"ref72","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/ajad.13069","article-title":"Method for successfully inducting individuals who use illicit fentanyl onto buprenorphine\/naloxone","volume":"30","author":"D Antoine","year":"2021","journal-title":"Am J Addict"},{"issue":"06","key":"ref73","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.annemergmed.2022.05.032","article-title":"A neuropharmacological model to explain buprenorphine induction challenges","volume":"80","author":"M K Greenwald","year":"2022","journal-title":"Ann Emerg Med"},{"key":"ref74","volume-title":"Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction","author":"Center for Substance Abuse Treatment","year":"2004"},{"issue":"02","key":"ref75","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0306-3623(91)90452-C","article-title":"Buprenorphine: bell-shaped dose-response curve for its antagonist effects","volume":"22","author":"I Lizasoain","year":"1991","journal-title":"Gen Pharmacol"},{"issue":"02","key":"ref76","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/ADM.0000000000000555","article-title":"Defining low-threshold buprenorphine treatment","volume":"14","author":"A Jakubowski","year":"2020","journal-title":"J Addict Med"},{"issue":"05","key":"ref78","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1377\/hlthaff.2019.01085","article-title":"Impact of long-term buprenorphine treatment on adverse health care outcomes in Medicaid","volume":"39","author":"H Samples","year":"2020","journal-title":"Health Aff (Millwood)"},{"key":"ref79","volume-title":"Effectiveness of Tapering from Methadone or Buprenorphine Maintenance Treatment Compared to Traditional Maintenance Treatment for People with Opiate Addiction: Systematic Review","author":"T K Dalsbo","year":"2017"},{"issue":"15","key":"ref80","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1517\/14656566.2014.955469","article-title":"Buprenorphine in the treatment of opioid addiction: opportunities, challenges and strategies","volume":"15","author":"X Li","year":"2014","journal-title":"Expert Opin Pharmacother"},{"issue":"05","key":"ref81","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/ADM.0000000000000166","article-title":"American Society of Addiction Medicine (ASAM) National Practice guideline for the use of medications in the treatment of addiction involving opioid use","volume":"9","author":"K Kampman","year":"2015","journal-title":"J Addict Med"},{"issue":"05","key":"ref82","first-page":"CD011117","article-title":"Opioid agonist treatment for pharmaceutical opioid dependent people","author":"S Nielsen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"02","key":"ref83","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/10826084.2017.1400064","article-title":"A systematic, intensive statistical investigation of data from the comprehensive analysis of reported drugs (CARD) for compliance and illicit opioid abstinence in substance addiction treatment with buprenorphine\/naloxone","volume":"53","author":"K Blum","year":"2018","journal-title":"Subst Use Misuse"},{"issue":"04","key":"ref84","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1360-0443.1998.9344753.x","article-title":"Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial","volume":"93","author":"W Ling","year":"1998","journal-title":"Addiction"},{"issue":"01","key":"ref85","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Y I Hser","year":"2014","journal-title":"Addiction"},{"issue":"02","key":"ref86","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2014","author":"R P Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"ref87","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1111\/bcp.13326","article-title":"QT interval prolongation in opioid agonist treatment: analysis of continuous 12-lead electrocardiogram recordings","volume":"83","author":"G K Isbister","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"03","key":"ref88","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/10550490050148099","article-title":"Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine","volume":"9","author":"N M Petry","year":"2000","journal-title":"Am J Addict"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.drugalcdep.2012.08.002","article-title":"Buprenorphine\/naloxone and methadone effects on laboratory indices of liver health: a randomized trial","volume":"128","author":"A J Saxon","year":"2013","journal-title":"Drug Alcohol Depend"},{"issue":"26","key":"ref90","first-page":"569","article-title":"Decline in drug overdose deaths after state policy changes - Florida, 2010-2012","volume":"63","author":"H Johnson","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"03","key":"ref91","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.drugalcdep.2013.04.006","article-title":"Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes","volume":"132","author":"Z Schuman-Olivier","year":"2013","journal-title":"Drug Alcohol Depend"},{"issue":"03","key":"ref92","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1176\/ajp.155.3.447-b","article-title":"Six deaths linked to misuse of buprenorphine-benzodiazepine combinations","volume":"155","author":"M Reynaud","year":"1998","journal-title":"Am J Psychiatry"},{"issue":"03","key":"ref93","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1521-0391.2012.12005.x","article-title":"Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data","volume":"22","author":"K Debelak","year":"2013","journal-title":"Am J Addict"},{"issue":"02","key":"ref94","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/AOG.0000000000000640","article-title":"Buprenorphine and naloxone compared with methadone treatment in pregnancy","volume":"125","author":"S L Wiegand","year":"2015","journal-title":"Obstet Gynecol"},{"key":"ref95","volume-title":"Highlights of prescribing information: Subutex (buprenorphine)","author":"Reckitt Benckiser Healthcare (UK) Ltd","year":"2002"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"108131","DOI":"10.1016\/j.drugalcdep.2020.108131","article-title":"Geographic proximity to buprenorphine treatment providers in the U.S","volume":"213","author":"J R Langabeer","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"01","key":"ref97","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/1874473711104010028","article-title":"Buprenorphine and buprenorphine\/naloxone diversion, misuse, and illicit use: an international review","volume":"4","author":"M A Yokell","year":"2011","journal-title":"Curr Drug Abuse Rev"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.drugalcdep.2018.09.007","article-title":"Understanding the use of diverted buprenorphine","volume":"193","author":"T J Cicero","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"ref99","first-page":"15","article-title":"Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration","volume":"45","author":"M C Meyer","year":"1984","journal-title":"J Clin Psychiatry"},{"key":"ref100","first-page":"147","article-title":"The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics","volume":"28","author":"K Verebey","year":"1981","journal-title":"NIDA Res Monogr"},{"issue":"04","key":"ref101","first-page":"CD001333","article-title":"Oral naltrexone maintenance treatment for opioid dependence","volume":"2011","author":"S Minozzi","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"J D Lee","year":"2018","journal-title":"Lancet"},{"issue":"02","key":"ref103","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0740-5472(85)90036-4","article-title":"Naltrexone","volume":"2","author":"H D Kleber","year":"1985","journal-title":"J Subst Abuse Treat"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.drugalcdep.2011.10.018","article-title":"Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course","volume":"123","author":"G E Bigelow","year":"2012","journal-title":"Drug Alcohol Depend"},{"issue":"00","key":"ref105","first-page":"33","article-title":"Naloxone, naltrexone, and related noroxymorphones","volume":"8","author":"H Blumberg","year":"1973","journal-title":"Adv Biochem Psychopharmacol"},{"issue":"03","key":"ref106","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/ajad.12711","article-title":"Antagonists in the medical management of opioid use disorders: historical and existing treatment strategies","volume":"27","author":"A Bisaga","year":"2018","journal-title":"Am J Addict"},{"issue":"03","key":"ref107","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/00952990.2011.653426","article-title":"Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice","volume":"38","author":"S C Sigmon","year":"2012","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"05","key":"ref108","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1176\/appi.ajp.2016.16050548","article-title":"Long-acting injectable naltrexone induction: a randomized trial of outpatient opioid detoxification with naltrexone versus buprenorphine","volume":"174","author":"M Sullivan","year":"2017","journal-title":"Am J Psychiatry"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.drugalcdep.2018.02.023","article-title":"Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: a phase 3 randomized trial","volume":"187","author":"A Bisaga","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"04","key":"ref110","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1360-0443.2006.01369.x","article-title":"Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review","volume":"101","author":"B A Johansson","year":"2006","journal-title":"Addiction"},{"issue":"03","key":"ref111","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1300\/J251v03n03_03","article-title":"The sequential use of clonidine and naltrexone in the treatment of opiate addicts","volume":"3","author":"M S Gold","year":"1984","journal-title":"Adv Alcohol Subst Abuse"},{"issue":"04","key":"ref112","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s002130100909","article-title":"Depot naltrexone: long-lasting antagonism of the effects of heroin in humans","volume":"159","author":"S D Comer","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"issue":"02","key":"ref113","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1176\/appi.ajp.2018.17070732","article-title":"A randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder","volume":"176","author":"M A Sullivan","year":"2019","journal-title":"Am J Psychiatry"},{"issue":"01","key":"ref114","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/add.14448","article-title":"Long-acting naltrexone has long-acting benefits and 100% induction rates are not difficult to achieve","volume":"114","author":"C Brewer","year":"2019","journal-title":"Addiction"},{"issue":"13","key":"ref115","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","article-title":"Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial","volume":"293","author":"J C Garbutt","year":"2005","journal-title":"JAMA"},{"issue":"02","key":"ref116","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.clinthera.2015.12.004","article-title":"Differentiating the effect of an opioid agonist on cardiac repolarization from \u00b5-receptor-mediated, indirect effects on the QT interval: a randomized, 3-way crossover study in healthy subjects","volume":"38","author":"B Darpo","year":"2016","journal-title":"Clin Ther"},{"issue":"02","key":"ref117","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1530-0277.2011.01601.x","article-title":"Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone","volume":"36","author":"J M Tetrault","year":"2012","journal-title":"Alcohol Clin Exp Res"},{"issue":"06","key":"ref118","doi-asserted-by":"crossref","first-page":"991","DOI":"10.15288\/jsad.2012.73.991","article-title":"Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection","volume":"73","author":"M C Mitchell","year":"2012","journal-title":"J Stud Alcohol Drugs"},{"issue":"04","key":"ref119","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/AOG.0000000000002864","article-title":"Pregnancy and naltrexone pharmacotherapy","volume":"132","author":"C W Jones","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"03","key":"ref120","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0890334404266881","article-title":"Transfer of naltrexone and its metabolite 6,beta-naltrexol into human milk","volume":"20","author":"C F Chan","year":"2004","journal-title":"J Hum Lact"},{"key":"ref121","volume-title":"REVIA\u00ae","author":"Duramed Pharmaceuticals Inc","year":"2013"},{"issue":"03","key":"ref122","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.anclin.2018.04.002","article-title":"Perioperative considerations for the patient with opioid use disorder on buprenorphine, methadone, or naltrexone maintenance therapy","volume":"36","author":"T K Harrison","year":"2018","journal-title":"Anesthesiol Clin"},{"issue":"06","key":"ref123","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1097\/ALN.0000000000001633","article-title":"To stop or not, that is the question: acute pain management for the patient on chronic buprenorphine","volume":"126","author":"T A Anderson","year":"2017","journal-title":"Anesthesiology"}],"container-title":["Seminars in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1787571.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T14:50:19Z","timestamp":1730818219000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1787571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":119,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2024,7,16]]},"published-print":{"date-parts":[[2024,8]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1787571","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0271-8235","1098-9021"],"issn-type":[{"value":"0271-8235","type":"print"},{"value":"1098-9021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,7]]}}}